Global Psoriasis Drugs
Market Report
2024
Psoriasis Drugs Market Report 2024 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Psoriasis Drugs Market Report 2024.
Global Psoriasis Drugs Market Report 2024 Market Size Split by Drug Class (Tumor Necrosis Factor Inhibitor, Interleukin Inhibitors, Others), by Treatment (Topical, Systemic, Biologics)
According to Cognitive Market Research, The Psoriasis Drugs Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Europe region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and is projected to grow at a CAGR of XX% in the future.
Asia Pacific accounted for a market share of over XX% of the global revenue with a USD XX million market size.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Psoriasis Drugs Market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Drug Class |
|
| Market Split by Treatment |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Psoriasis Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Psoriasis Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Psoriasis Drugs Market Report Description
Introduction of The Psoriasis Drugs Market
Psoriasis is a skin disease that causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term (chronic) disease with no cure. It can be painful, interfere with sleep and make it hard to concentrate. The condition tends to go through cycles, flaring for a few weeks or months, then subsiding for a while. Common triggers in people with a genetic predisposition to psoriasis include infections, cuts or burns, and certain medications.
The growth of the market is contributed to a number of factors, including patient preferences, aging populations, new therapy introductions, and regulatory approvals, will contribute to the rise over the projection period. Progress in R&D, biologics and targeted treatments, oral small molecule medicines, personalized medicine, telemedicine and digital health, patient-centric care, biosimilars, artificial intelligence, and machine learning are some of the major trends that are expected to emerge over the projected period.
Market Dynamics of the Psoriasis Drugs Market
Key Drivers for The Psoriasis Drugs Market
- Growing prevalence of psoriasis to boost psoriasis drugs market growth.
The main driver that increased the demand for psoriasis drugs is the growing prevalence of patients suffering from psoriasis. Over 8 million Americans suffer from psoriasis, according to data released by the National Psoriasis Foundation in 2023. Additionally, in an effort to better inform patients on the management of psoriasis, the government and businesses involved in the industry are initiating a number of awareness campaigns. In addition, it is projected that the introduction of new medications to speed up the treatment of psoriasis will support market expansion in the years to come.
For instance, in Nov 2020, Bristol Myers Squibb introduced Deucravacitinib (BMS-986165) in individuals with psoriatic arthritis was shown to be safe and effective in late-breaking Phase 2 data. It encourages patients who are wary of injectables to use them more effectively.
Source:(https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study/default.aspx)
For instance, in June 2023, the American Academy of Dermatology, in collaboration with Boehringer Ingelheim International GmbH, launched innovative breakthrough project to develop educational resources with an aim to improve the evaluation, diagnosis, and treatment of patients suffering from Generalized Pustular Psoriasis (GPP).
Source:(https://www.aad.org/news/aad-generalized-pustular-psoriasis-education-initiative#:~:text=(June%2022%2C%202023)%20%E2%80%93,resources%20to%20improve%20the%20evaluation%2C)
Therefore, the growing incidence of patients suffering from psoriasis drives the market for psoriasis drugs.
- An increase in R&D funding by private and public organizations propelled the market growth of psoriasis drug market.
Increased research and development (R&D) funding from both private and public organizations has propelled growth in the psoriasis drug market. This surge in funding has enabled accelerated innovation in therapies aimed at managing and potentially curing psoriasis. With more resources allocated to R&D, pharmaceutical companies and research institutions can conduct extensive clinical trials, develop novel drug formulations, and explore combined drug therapy approaches tailored to psoriasis patients. Furthermore, enhanced funding supports the expansion of infrastructure for diagnosis, treatment, and patient care, fostering a more robust ecosystem for psoriasis management. Ultimately, these investments contribute to the discovery of more effective treatments and improved outcomes for individuals living with psoriasis disease.
For instance, in Nov 2020, Bristol Myers Squibb introduced Deucravacitinib (BMS-986165) in individuals with psoriatic arthritis was shown to be safe and effective in late-breaking Phase 2 data. It encourages patients who are wary of injectables to use them more effectively.
Source:(https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study/default.aspx)
For instance, in July 2023, the National Psoriasis Foundation (NPF) announced $3.4 million in awards to researchers studying psoriatic disease, including nine awards for research on PsA prevention, treatment, and mechanisms. NPF's strategic plan focuses on transformational research that can help treat psoriatic disease and answer questions about the disease's underlying mechanisms, comorbidities, and public health.
Source:(https://www.psoriasis.org/2023-npf-grant-and-fellowship-awards-announced/#:~:text=This%20year%2C%20NPF%20is%20proud,live%20with%20PsA%20and%20psoriasis.)
For instance, in September 2023, the Psoriasis Association announced that it would continue funding its Biomarkers of Systemic Treatment Outcomes in Psoriasis (BSTOP) program in 2023. The organization also considered funding smaller research projects with one-off grants in 2024.
Source:(https://www.psoriasis-association.org.uk/news/researchgrantcall#:~:text=We%20will%20be%20continuing%20our%20funding%20commitment,projects%20with%20one%20off%20grants%20next%20year.)
Increased R&D funding from private and public sectors has catalyzed innovation in psoriasis treatments, including new drugs and gene therapies, while also bolstering diagnostic capabilities and patient care infrastructure. This investment is crucial for advancing therapies and improving outcomes for individuals living with psoriasis disease.
Restraint Factor for The Psoriasis Drugs Market
- High medication costs to restrict market growth of psoriasis drugs.
Psoriasis is a chronic condition that may be quite expensive to the middle-class economy. The economic study of treating psoriasis indicates that the cost of medications for this condition makes up around 20% of the overall expenses. According to the NPF, it was estimated that one in three people with the condition had trouble paying for the cost of treatment, and a tube of topical medications would cost between USD 500 to USD 600.
For instance, as per a 2021 article published in the National Center for Biotechnology Information (NCBI), the out-of-pocket cost of biologics could range from around USD 4,423 to USD 6,950 per year.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444058/)
Thus, high drug prices and the absence of supportive reimbursement policies in developing countries are a couple of the factors limiting the market growth throughout the forecast period, despite the rising incidence of psoriasis and other associated conditions.
How did COVID-19 impact The Psoriasis Drugs Market
The psoriasis market was originally negatively impacted by the COVID-19 pandemic, mostly due to advice released by regulatory organizations indicating that those undergoing treatment for psoriasis are more susceptible to contracting COVID-19. Coronavirus has affected people all across the globe. For those with chronic health conditions like psoriasis, there is concern about COVID-19 and the risk of complications in an already fragile immune system. Psoriasis medications that treat the condition suppress the immune system. These medications have made the immune system susceptible to certain infections such as COVID-19. The researchers could not find any proof that stopping or changing psoriasis and psoriatic arthritis medication treatments would reduce the chance of contracting COVID-19. It is anticipated that these rules would accelerate market expansion during the epidemic.
For instance, according to a 2021 report in the British Journal of Dermatology, people with psoriasis have a 36% increased risk for infection and a 33% increased risk of death due to infection. That risk exists with and without factors related to comorbidity (existing conditions).
Source:(https://www.verywellhealth.com/psoriasis-and-covid-19-5190781#:~:text=According%20to%20a%202021%20report,to%20comorbidity%20(existing%20conditions).)
For instance, Data were presented at the American Academy of Dermatology Virtual Meeting Experience 2021 regarding the connection between psoriasis and COVID-19 risk and systemic (whole-body) treatments for psoriasis and how they might contribute to risk.
Source:(https://www.dermatologytimes.com/view/researchers-study-connection-between-psoriasis-and-covid-19)
Opportunities for The Psoriasis Drugs Market
- Increasing focus on creating biologics to treat psoriasis represents a significant opportunity to drive the market growth of psoriasis drugs.
People with psoriasis disease are looking for effective solutions to control their disease. Topical and systemic medications were the condition's usual treatments in the past. On the other hand, the care of psoriasis has changed dramatically with the advent of biologics. Biologics offer excellent efficacy with few adverse effects by targeting certain checkpoints in the inflammatory pathways. Many businesses have redirected their efforts toward the development of biologics as a result of the advantages attached to them. Government and regulatory agencies are also creating favorable conditions for the development and introduction of novel biologics for the treatment of psoriasis.
For instance, in October 2023, UCB S.A. received approval from the U.S. Food and Drug Administration (U.S. FDA) for its drug, BIMZELX, an IL-17A and IL-17F inhibitor for treating adult patients suffering from moderate-to-severe plaque psoriasis.
Source:(https://www.ucb.com/stories-media/Press-Releases/article/BIMZELXR-Approved-by-the-US-FDA-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Plaque-Psoriasis)
For instance, in September 2022, Boehringer Ingelheim International GmbH received U.S. FDA clearance for its drug, SPEVIGO, an interleukin-36 receptor inhibitor. The drug was developed to treat adult patients suffering from Generalized Pustular Psoriasis (GPP).
Source:(https://www.boehringer-ingelheim.com/us/human-health/skin-and-inflammatory-diseases/gpp/fda-approves-first-treatment-option-generalized)
Therefore, the rising development of biologics to treat psoriasis disease creates need for the psoriasis drugs thereby driving the growth of the market.
We have various report editions of Psoriasis Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Psoriasis Drugs Market
Prominent market players are heavily investing in R&D to expand their product lines, which will contribute to the further growth of the psoriasis treatment market. In order to expand their global reach, market players are also pursuing a variety of strategic measures, such as joint ventures, product launches, contracts, mergers and acquisitions, higher investments, and cooperation with other institutions. In order to grow and thrive in a market that is becoming more and more competitive, companies in the psoriasis treatment sector need to provide reasonably priced products.
For instance, in June 2022 Fosun Pharma and Amgen have together announced a collaboration and license agreement for Fosun Pharma for the commercialization of Amgen’s Otezla and Parsabiv in the Chinese Mainland. The collaboration will enable Amgen to bring the two innovative medicines to Chinese patients with psoriasis and chronic kidney disease more quickly by leveraging Fosun Pharma’s commercial capabilities within China.
Source:(https://www.fiercepharma.com/pharma/amgen-partners-fosun-pharma-bring-psoriasis-chronic-kidney-disease-medicines-country)
Top Companies Market Share in Psoriasis Drugs Industry: (In no particular order of Rank)
- AbJohnson & Johnson Services
- Inc.
- Pfizer Inc.
- LEO Pharma A/S
- Novartis AG
- Merck & Co.
- Inc.
- UCB S.A.
- AbbVie Inc.
- Sun Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Amgen Inc.
- Evelo Biosciences
- Inc
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of the Psoriasis Drugs Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, The North America region dominated the Psoriasis Drugs market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. North America is the most significant global psoriasis drug market shareholder and is expected to expand substantially during the forecast period. As the psoriasis disease is so common in North America region, there are many modern healthcare facilities there, and major market players are there, North America holds a sizable share of the worldwide market for psoriasis drugs. According to a JAMA Network article, psoriasis is one of the most common skin conditions in the US. Roughly 7 million individuals in the US are anticipated to be affected, or 3% of the adult population. Furthermore, the favorable reimbursement policies and the increasing use of biologics in the treatment of psoriasis are driving the regional market expansion. In addition, additional new medications have been approved by regulatory agencies to treat psoriasis.
For instance, in October 2023, UCB, an international biopharmaceutical company, revealed that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) to be used in treating moderate-to-severe plaque psoriasis in people eligible for systemic therapy or phototherapy. BIMZELX is the initial and sole authorized psoriasis remedy that blocks two crucial cytokines that stimulate inflammatory reactions – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Source:(https://www.ucb.com/stories-media/Press-Releases/article/BIMZELXR-Approved-by-the-US-FDA-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Plaque-Psoriasis)
Moreover, in October 2023 the US FDA approved abatacept (Orencia) to treat psoriatic arthritis (PsA) in pediatric patients two years of age and older.
Source:(https://www.medscape.com/viewarticle/997925#:~:text=The%20US%20Food%20and%20Drug,juvenile%20idiopathic%20arthritis%20(JIA).)
For instance, in November 2021 – AbbVie limited was granted approval by the European Commission regarding SKYRIZI which is a subcutaneous injection. This product is expected to heel active psoriatic arthritis.
Source:(https://news.abbvie.com/2022-11-23-AbbVie-Announces-European-Commission-Approval-of-SKYRIZI-R-risankizumab-for-the-Treatment-of-Moderate-to-Severe-Active-Crohns-Disease)
Which Region Is Expanding at The Fastest CAGR?
The Europe Region’s Psoriasis Drugs market is expected to experience the fastest growth rate with a CAGR of XX% during the forecast period. Europe is a significant market for psoriasis drugs due to the growing incidence of psoriasis, increased healthcare spending, and advantageous drug approval laws. In the United Kingdom, psoriasis affects around one to two million people. Additionally, more research is being done to create drugs that effectively treat psoriasis.
For instance, in February 2024, academic researchers from King's College London studied the initial impacts of an immunosuppressant medicine called IL-23 inhibitor risankizumab. This study might help doctors create psoriasis treatment plans that are specifically suited to each patient. The study reveals that the medicine effects skin cells before any clinical signs. The European market is growing as a result of several causes.
Source:(https://www.kcl.ac.uk/news/understanding-early-effects-of-psoriasis-drug-offers-potential-for-personalised-treatment)
For instance, in May 2023, Sareum Holdings PLC received approval from the Therapeutic Goods Administration, Australia, to commence phase I clinical trial of its drug SDC-1801 intended for treating patients suffering from psoriasis.
Source:(https://www.clinicaltrialsarena.com/news/sareum-approval-sdc-1801-australia/)
For instance, in August 2020, Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis.
Source:(https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis)
The current report Scope analyzes Psoriasis Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Psoriasis Drugs Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Psoriasis Drugs Market Analysis
Global Psoriasis Drugs Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Psoriasis Drugs Industry growth. Psoriasis Drugs market has been segmented with the help of its Drug Class, Treatment , and others. Psoriasis Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Psoriasis Drugs Market
Drug Class Segment Analysis
Interleukin inhibitors are expected to expand at the quickest rate. Interleukin inhibitors help patients because they are safer and more effective than other psoriasis medication classes, which regularly results in higher patient uptake. Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guselkumab), Ilumya (Tildrakizumab), SKYRIZI (Risankizumab), and other major licensed antibodies target interleukins. The segment is expanding as a result of medication approvals granted by regulatory bodies.
For instance, in November 2022, ACELYRIN, INC. commenced a phase 2/3 clinical trial to study the safety and efficacy of Izokibep, an IL17A protein inhibitor, in patients suffering from psoriatic arthritis. The study is expected to be completed by 2024.
Source:(https://classic.clinicaltrials.gov/ct2/show/NCT05623345)
For instance, in January 2022, AbbVie received United States Food and Drug Administration approval for SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for treating adults with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and impacts approximately 30% of psoriasis patients.
Source:(https://news.abbvie.com/2022-01-21-U-S-FDA-Approves-Second-Indication-for-SKYRIZI-R-risankizumab-rzaa-to-Treat-Adults-with-Active-Psoriatic-Arthritis)
For instance, in April 2023, UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union
Source:(https://www.ucb.com/stories-media/Press-Releases/article/UCB-Receives-Positive-CHMP-Opinions-for-Bimekizumab-for-the-Treatment-of-Adults-with-Psoriatic-Arthritis-and-Axial-Spondyloarthritis-in-the-European-Union)
Psoriasis Drugs Market Share (%) by Drug Class in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Psoriasis Drugs Industry. Request a Free Sample PDF!
Treatment Segment Analysis
The biologics segment is dominant because it includes several items with strong adoption patterns. In addition, biologics have significant advantages for the management of psoriasis, such as better patient outcomes, reduced treatment duration, increased efficacy, and the possibility of a more individualized approach. Biologics for psoriasis include golimumab, etanercept, tildrakizumab, secukinumab, and others.
For instance, in April 2023, UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union
Source:(https://www.ucb.com/stories-media/Press-Releases/article/UCB-Receives-Positive-CHMP-Opinions-for-Bimekizumab-for-the-Treatment-of-Adults-with-Psoriatic-Arthritis-and-Axial-Spondyloarthritis-in-the-European-Union)
For instance, the newest biologic agent for psoriasis, bimekizumab (Bimzelx), was approved by the FDA on October 18, 2023, for the management of moderate to severe psoriasis. Bimekizumab is unique in that it blocks both the IL-17A and IL-17F cytokines.
Source:(https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond)
Psoriasis Drugs Market Share (%) by Treatment in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the Psoriasis Drugs market, it can be concluded that the market for psoriasis drugs worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Psoriasis Drugs Market
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_expenditure_statistics
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Psoriasis Drugs Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Class | Tumor Necrosis Factor Inhibitor, Interleukin Inhibitors, Others |
| Treatment | Topical, Systemic, Biologics |
| List of Competitors | AbJohnson & Johnson Services, Inc., Pfizer Inc., LEO Pharma A/S, Novartis AG, Merck & Co., Inc., UCB S.A., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Amgen Inc., Evelo Biosciences, Inc |
This chapter will help you gain GLOBAL Market Analysis of Psoriasis Drugs. Further deep in this chapter, you will be able to review Global Psoriasis Drugs Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Psoriasis Drugs Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Psoriasis Drugs Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Psoriasis Drugs Revenue Market Size By Region
-
-
1.3 Global Psoriasis Drugs Market Size By Drug Class 2019 -2031
-
1.3.1 Tumor Necrosis Factor Inhibitor Market Size
-
1.3.2 Interleukin Inhibitors Market Size
-
1.3.3 Others Market Size
-
-
1.4 Global Psoriasis Drugs Market Size By Treatment 2019 -2031
-
1.4.1 Topical Market Size
-
1.4.2 Systemic Market Size
-
1.4.3 Biologics Market Size
-
-
1.5 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.6 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.6.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.6.2 Global Market Revenue Split By Drug Class
-
1.6.3 Global Market Revenue Split By Treatment
-
1.6.4 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Psoriasis Drugs Market Size 2019 - 2031
-
2.1.1 North America Psoriasis Drugs Market Size By Country 2019 - 2031
-
2.1.2 North America Psoriasis Drugs Market Size by Drug Class 2019 -2031
-
2.1.2.1 North America Tumor Necrosis Factor Inhibitor Market Size
-
2.1.2.2 North America Interleukin Inhibitors Market Size
-
2.1.2.3 North America Others Market Size
-
-
2.1.3 North America Psoriasis Drugs Market Size by Treatment 2019 -2031
-
2.1.3.1 North America Topical Market Size
-
2.1.3.2 North America Systemic Market Size
-
2.1.3.3 North America Biologics Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Psoriasis Drugs Market Size 2019 - 2031
-
3.1.1 Europe Psoriasis Drugs Market Size By Country 2019 - 2031
-
3.1.2 Europe Psoriasis Drugs Market Size by Drug Class 2019 -2031
-
3.1.2.1 Europe Tumor Necrosis Factor Inhibitor Market Size
-
3.1.2.2 Europe Interleukin Inhibitors Market Size
-
3.1.2.3 Europe Others Market Size
-
-
3.1.3 Europe Psoriasis Drugs Market Size by Treatment 2019 -2031
-
3.1.3.1 Europe Topical Market Size
-
3.1.3.2 Europe Systemic Market Size
-
3.1.3.3 Europe Biologics Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Psoriasis Drugs Market Size 2019 - 2031
-
4.1.1 Asia Pacific Psoriasis Drugs Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Psoriasis Drugs Market Size by Drug Class 2019 -2031
-
4.1.2.1 Asia Pacific Tumor Necrosis Factor Inhibitor Market Size
-
4.1.2.2 Asia Pacific Interleukin Inhibitors Market Size
-
4.1.2.3 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Psoriasis Drugs Market Size by Treatment 2019 -2031
-
4.1.3.1 Asia Pacific Topical Market Size
-
4.1.3.2 Asia Pacific Systemic Market Size
-
4.1.3.3 Asia Pacific Biologics Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Psoriasis Drugs Market Size 2019 - 2031
-
5.1.1 South America Psoriasis Drugs Market Size By Country 2019 - 2031
-
5.1.2 South America Psoriasis Drugs Market Size by Drug Class 2019 -2031
-
5.1.2.1 South America Tumor Necrosis Factor Inhibitor Market Size
-
5.1.2.2 South America Interleukin Inhibitors Market Size
-
5.1.2.3 South America Others Market Size
-
-
5.1.3 South America Psoriasis Drugs Market Size by Treatment 2019 -2031
-
5.1.3.1 South America Topical Market Size
-
5.1.3.2 South America Systemic Market Size
-
5.1.3.3 South America Biologics Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Psoriasis Drugs Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Psoriasis Drugs Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Psoriasis Drugs Market Size by Drug Class 2019 -2031
-
6.1.2.1 Middle East and Africa Tumor Necrosis Factor Inhibitor Market Size
-
6.1.2.2 Middle East and Africa Interleukin Inhibitors Market Size
-
6.1.2.3 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Psoriasis Drugs Market Size by Treatment 2019 -2031
-
6.1.3.1 middle_east_and_africa_title} Topical Market Size
-
6.1.3.2 middle_east_and_africa_title} Systemic Market Size
-
6.1.3.3 middle_east_and_africa_title} Biologics Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Psoriasis Drugs Market Size by Drug Class 2019 -2031
-
7.1.2 Country 1Psoriasis Drugs Market Size by Treatment 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Psoriasis Drugs Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 AbJohnson & Johnson Services
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 LEO Pharma A/S
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Novartis AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Merck & Co.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 UCB S.A.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 AbbVie Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Sun Pharmaceutical Industries Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Eli Lilly and Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Amgen Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Evelo Biosciences
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Drug Class Analysis 2019 -2031, will provide market size split by Drug Class. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Class Analysis 2019 -2031
-
10.1 Tumor Necrosis Factor Inhibitor
-
10.1.1 Global Psoriasis Drugs Revenue Market Size and Share by Tumor Necrosis Factor Inhibitor 2019 -2031
-
-
10.2 Interleukin Inhibitors
-
10.2.1 Global Psoriasis Drugs Revenue Market Size and Share by Interleukin Inhibitors 2019 -2031
-
-
10.3 Others
-
10.3.1 Global Psoriasis Drugs Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Treatment Analysis 2019 -2031
-
11.1 Topical
-
11.1.1 Global Psoriasis Drugs Revenue Market Size and Share by Topical 2019 - 2031
-
-
11.2 Systemic
-
11.2.1 Global Psoriasis Drugs Revenue Market Size and Share by Systemic 2019 - 2031
-
-
11.3 Biologics
-
11.3.1 Global Psoriasis Drugs Revenue Market Size and Share by Biologics 2019 - 2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Psoriasis Drugs market
Chapter 12 Research Findings
-
12.1 Key Takeaways
-
12.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
12.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Psoriasis Drugs Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Psoriasis Drugs Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Psoriasis Drugs Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Psoriasis Drugs Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Psoriasis Drugs Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Psoriasis Drugs Market
Key Questions Answered By Psoriasis Drugs Market Report 2024
| Why Tumor Necrosis Factor Inhibitor have a significant impact on Psoriasis Drugs market? |
| What are the key factors affecting the Tumor Necrosis Factor Inhibitor and Interleukin Inhibitors of Psoriasis Drugs Market? |
| What is the CAGR/Growth Rate of Topical during the forecast period? |
| By type, which segment accounted for largest share of the global Psoriasis Drugs Market? |
| Which region is expected to dominate the global Psoriasis Drugs Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
